Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros, Inc. (Nasdaq: NEPH) is a water technology company focused on filtration products, services, and water-quality education for medical, healthcare, commercial, and industrial markets. The NEPH news feed highlights how the company’s filtration solutions and educational initiatives are applied in practice, as well as how its financial performance evolves over time.
News about Nephros often includes quarterly and year-to-date financial results, where the company reports net revenue, net income or loss, gross margin, and adjusted EBITDA. These updates frequently discuss programmatic revenue tied to recurring filter use, emergency response sales related to compromised water events, and trends in service revenue. Investors can use these releases to understand how Nephros’ programmatic business and active customer sites are developing across infection control, dialysis water, and commercial segments.
The NEPH news stream also covers product launches and technology developments. Examples include new filtration products designed to support compliance with water quality standards and to extend Nephros’ technology into additional medical, commercial, and industrial applications. These announcements explain how new offerings fit within the company’s portfolio and which types of facilities or industries they are intended to serve.
Another recurring theme in Nephros news is water safety education. The company reports on webinars, speaking engagements, and the activities of the Nephros Water Institute, which provides regulatory and risk-based educational programming for professionals responsible for water systems. Together, these financial, product, and educational updates give a rounded view of Nephros’ operations and strategic focus. Users interested in NEPH can review this page regularly for the latest company-issued press releases and related disclosures.
Nephros anticipates $1.6 million in net revenues for Q2 2020, marking a 33% decline compared to the same quarter in 2019. The company ended the quarter with approximately $7.0 million in cash. This revenue decrease halted a four-year growth streak, largely attributed to COVID-19 challenges. CEO Daron Evans expressed optimism about future growth, citing rising focus on pathogens beyond COVID-19 and promising products like PluraPath, SequaPath, and DialyPath. However, there are risks related to delays in customer acquisitions due to potential new COVID-19 restrictions.
Nephros, a water purification and pathogen detection company, announced its inclusion in the Russell Microcap® Index effective June 29, 2020. This recognition is seen as a significant milestone in its growth trajectory, expected to enhance Nephros' visibility and expand its shareholder base. Inclusion in the Russell index supports the company's stature among institutional investors, with approximately $9 trillion in assets benchmarked against Russell's indexes. The company develops ultrafilters used in hospitals and pathogen detection systems for real-time water quality monitoring.
Nephros, Inc. (Nasdaq: NEPH) announced its participation in the Virtual Summer Summit scheduled for June 9, 2020, at 10:55 AM ET. Andy Astor, the company's COO & CFO, will present and field questions from investors. Nephros specializes in high-performance water purification products and pathogen detection systems for medical and commercial markets, including hospitals and dialysis centers. Interested parties can access the webcast presentation and register for the event via Nephros's official links.
Nephros, Inc. (Nasdaq: NEPH) has announced a change to its 2020 Annual Meeting of Stockholders, which will now be conducted via webcast on May 21, 2020, at 9:00 a.m. Eastern Time, due to public health concerns related to the coronavirus. Stockholders of record as of March 25, 2020, are encouraged to participate and vote online. After the meeting, management will provide business overviews and a Q&A session. Stockholders can submit questions through the virtual meeting platform.
Nephros reported a 43% increase in net revenue, reaching $2.5 million for Q1 2020, up from $1.8 million in Q1 2019. The company's net loss improved by 19%, totaling $1.1 million. Adjusted EBITDA showed a 7% improvement, at ($0.8 million). Gross margins increased to 59% from 56%. R&D expenses decreased by 26% to $0.6 million, while SG&A expenses rose by 30%, totaling $1.9 million. Nephros held $9.0 million in cash and equivalents as of March 31, 2020.
Summary not available.